“That was NP who gave that impression. However during the webcast he read verbatim from the DSMC report which listed only 3 checkboxes and halting for efficacy was not one of them. It was never in play.”

Interesting thought. I found it strange that the option for the DSMC to halt the trial due to efficacy wasn’t listed as an option in the PR despite NP stating this was one of the options numerous times in the previous months. He either didn’t understand the options/capabilities of a DSMC (simulator to his idea of a 50 patient analysis despite that never being an option) or he purposefully didn’t list the halting option because it would make the 2nd best option seem less “great.”